AR124036A1 - Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición - Google Patents
Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composiciónInfo
- Publication number
- AR124036A1 AR124036A1 ARP210103113A ARP210103113A AR124036A1 AR 124036 A1 AR124036 A1 AR 124036A1 AR P210103113 A ARP210103113 A AR P210103113A AR P210103113 A ARP210103113 A AR P210103113A AR 124036 A1 AR124036 A1 AR 124036A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- pharmaceutically acceptable
- salt
- composition
- pharmaceutical composition
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 9
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical class [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000001768 cations Chemical class 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se revela una composición farmacéutica que comprende: (i) una sal de fórmula (3), dicha sal que es una combinación de un compuesto de fórmula (1) y un ácido de fórmula (2) en una proporción de 1:n, en donde X es H ó OH, Y es H o un catión que se selecciona del grupo integrado por Li, Na y K, ⁻ ⁻ ⁻ es un enlace simple o un enlace doble, y n es 0,5 ó 1, (ii) L-DOPA o una sal farmacéuticamente aceptable del mismo, y (iii) de modo opcional un excipiente, portador y/o diluyente farmacéuticamente aceptable. La composición farmacéutica puede usarse en el tratamiento de la enfermedad del Parkinson. Reivindicación 1: Una composición farmacéutica que comprende: (i) una sal de fórmula (3), dicha sal que es una combinación de un compuesto de fórmula (1) y un ácido de fórmula (2) en una proporción de 1:n, en donde X es H ó OH, Y es H o un catión que se selecciona del grupo integrado por Li, Na y K, ⁻ ⁻ ⁻ es un enlace simple o un enlace doble, y n es 0,5 ó 1, (ii) L-DOPA o una sal farmacéuticamente aceptable del mismo, y (iii) de modo opcional un excipiente, portador y/o diluyente farmacéuticamente aceptable. Reivindicación 2: La composición farmacéutica de acuerdo con reivindicación 1, donde los siguientes valores aplican para la sal de fórmula (3): X es OH, Y es H, y ⁻ ⁻ ⁻ es un enlace simple, por consiguiente proporcionando una sal de fórmula (4) que es una combinación de un compuesto de fórmula (1) y ácido tartárico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20206645 | 2020-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124036A1 true AR124036A1 (es) | 2023-02-08 |
Family
ID=73288427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103113A AR124036A1 (es) | 2020-11-10 | 2021-11-09 | Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220168242A1 (es) |
| EP (1) | EP4243801A1 (es) |
| JP (1) | JP2023548429A (es) |
| KR (1) | KR20230106659A (es) |
| CN (1) | CN116685314A (es) |
| AR (1) | AR124036A1 (es) |
| AU (1) | AU2021378472A1 (es) |
| CA (1) | CA3198266A1 (es) |
| TW (1) | TW202233169A (es) |
| WO (1) | WO2022101227A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024062344A1 (en) * | 2022-09-21 | 2024-03-28 | Assia Chemical Industries Ltd. | Solid state forms of mesdopetam and salts therof |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101203511A (zh) | 2005-06-23 | 2008-06-18 | 阿斯利康(瑞典)有限公司 | 作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物 |
| RU2593500C2 (ru) | 2011-04-19 | 2016-08-10 | Интегрейтив Ресерч Лэборэторис Свиден АБ | Новые модуляторы кортикальной дофаминергической и опосредованной nmda-рецептором глутаматергической нейротрансмиссии |
| WO2020110128A1 (en) | 2018-11-29 | 2020-06-04 | Prilenia Neurotherapeutics Ltd. | Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia |
| EP3976581B1 (en) * | 2019-05-24 | 2023-11-22 | Irl 790 AB | Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine |
-
2021
- 2021-11-09 KR KR1020237019294A patent/KR20230106659A/ko unknown
- 2021-11-09 EP EP21799308.8A patent/EP4243801A1/en active Pending
- 2021-11-09 AR ARP210103113A patent/AR124036A1/es unknown
- 2021-11-09 AU AU2021378472A patent/AU2021378472A1/en active Pending
- 2021-11-09 CA CA3198266A patent/CA3198266A1/en active Pending
- 2021-11-09 TW TW110141661A patent/TW202233169A/zh unknown
- 2021-11-09 CN CN202180089407.4A patent/CN116685314A/zh active Pending
- 2021-11-09 JP JP2023550714A patent/JP2023548429A/ja active Pending
- 2021-11-09 WO PCT/EP2021/081162 patent/WO2022101227A1/en active Application Filing
- 2021-11-09 US US17/454,110 patent/US20220168242A1/en not_active Abandoned
-
2023
- 2023-09-06 US US18/461,791 patent/US20240148674A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4243801A1 (en) | 2023-09-20 |
| CA3198266A1 (en) | 2022-05-19 |
| AU2021378472A1 (en) | 2023-06-15 |
| WO2022101227A1 (en) | 2022-05-19 |
| CN116685314A (zh) | 2023-09-01 |
| TW202233169A (zh) | 2022-09-01 |
| KR20230106659A (ko) | 2023-07-13 |
| JP2023548429A (ja) | 2023-11-16 |
| US20220168242A1 (en) | 2022-06-02 |
| US20240148674A1 (en) | 2024-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124036A1 (es) | Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición | |
| CO2023000199A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
| BRPI0518846A2 (pt) | composto, composiÇço farmacÊutica, mÉtodos de tratar, ou reduzir o risco de doenÇas ou condiÇÕes em que inibiÇço da enzima mpo É benÉfica e de tratar, ou reduzir o risco de distérbios neuroinflamatàrios, uso de um composto, e, processo para a preparaÇço de um composto | |
| BR112022010254A2 (pt) | Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio | |
| UY30438A1 (es) | Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos | |
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| CO2023002852A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| BRPI0516454A (pt) | compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, sua utilização, método para o tratamento e profilaxia de enfermidades, e de diabetes do tipo ii | |
| CO6220902A2 (es) | Formulacion en polvo del valganciclovir | |
| UY39032A (es) | Compuestos heterocíclicos como agentes antivirales | |
| BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
| BR112014001083A8 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| MX2023003846A (es) | Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo. | |
| CO2023002940A2 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| UY39681A (es) | Derivados de ciclobutilo 1,3–sustituidos y sus usos | |
| DOP2021000254A (es) | Compuestos de pirrolidina | |
| CO2024002844A2 (es) | Compuestos espirocíclicos | |
| PH12021550557A1 (en) | Furo[3,4-b]pyrrole-containing btk inhibitor | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| MX2023006193A (es) | Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina. | |
| BR0312452A (pt) | Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; e método para o tratamento e/ou profilaxia de doenças que são moduladas por agonistas de ppar(alfa) e/ou ppar(gama) |